九典制药(300705) - 2023 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2023 reached ¥501,873,303.51, an increase of 11.6% compared to ¥449,062,914.36 in the same period last year[10] - The company's operating revenue for the current period was ¥501,873,303.51, representing an increase of 11.76% compared to the same period last year[11] - Net profit attributable to shareholders was ¥76,890,546.67, reflecting a growth of 37.39% year-over-year[11] - The net profit after deducting non-recurring gains and losses was ¥68,951,769.31, up by 26.57% from the previous year[11] - Basic and diluted earnings per share were both ¥0.22, marking a 29.41% increase year-over-year[11] - The company's operating profit for the current period was ¥85,861,272.00, an increase from ¥62,420,990.62 in the same period last year[20] Cash Flow - The net cash flow from operating activities reached ¥98,228,739.03, a significant increase of 5,414.59% compared to the same period last year[11] - The net cash flow from operating activities for the first quarter was ¥98,228,739.03, a significant increase of 5,414.59% compared to the previous period's net cash flow of -¥1,848,282.70[33] - The net cash flow from investing activities was -¥133,995,556.50, a decline of 258.52% compared to the previous period's net cash flow of ¥84,526,583.21, mainly due to increased long-term asset investments[33] - The net cash flow from financing activities was ¥47,040,354.71, a significant increase of 1,267.54% from the previous period's net cash flow of -¥4,029,029.69, primarily due to increased project loans[33] Assets and Liabilities - Total assets as of March 31, 2023, were ¥2,440,348,127.68, compared to ¥2,299,671,112.18 at the start of the year, reflecting a growth of 6.1%[9] - Total liabilities increased to ¥798,462,601.25 from ¥747,050,467.29, marking a rise of 6.5%[9] - The company's inventory as of Q1 2023 was ¥278,058,701.01, up from ¥241,039,257.35, indicating a growth of 15.3%[6] - Short-term borrowings rose to ¥81,394,373.89 from ¥71,568,322.23, an increase of 13.0%[9] - Total cash and cash equivalents at the end of the period amounted to ¥346,323,811.83, down from ¥455,046,435.86 in the previous period[31] Equity - The total equity attributable to shareholders reached ¥1,641,885,526.43, up from ¥1,552,620,644.89, reflecting a growth of 5.7%[9] - The total equity attributable to shareholders was ¥1,641,885,526.43, reflecting a growth of 5.75% compared to the previous year[11] Expenses - Research and development expenses increased to ¥42,597,978.69, compared to ¥34,289,853.06 in the previous year[20] - Operating costs increased to ¥125,938,556.98, reflecting a 34.17% rise compared to ¥93,861,775.81 in the previous period, primarily due to changes in revenue and product mix[33] - Management expenses surged by 78.47% to ¥19,361,866.30, up from ¥10,848,534.97, mainly due to increased equity incentive costs[33] - The company reported a 41.47% increase in income tax expenses to ¥8,983,704.23, up from ¥6,350,186.61, due to increased profits[33] Shareholder Information - The company reported a total of 3,154,206 shares held by individual shareholder Lü Jubao, representing 0.92% of total shares[36] - Major shareholders include Zhu Zhihong with 29,368,500 shares and a significant stake held by various investment funds[36] - The company has not disclosed any relationships or concerted actions among the top shareholders[36] Audit and Compliance - The first quarter report has not been audited, ensuring the financial data's integrity[46] - The company guarantees the accuracy and completeness of the quarterly report, with all board members assuming legal responsibility[42] - There are no adjustments or restatements required for previous accounting data[47] Government Subsidies - The company received government subsidies amounting to ¥9,038,368.49 during the current period[12] - The company received government subsidies, contributing to a 582.44% increase in other income to ¥9,223,493.74 from ¥1,351,554.00 in the previous period[33]